State Street’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-2,384,677
| Closed | -$162M | – | 4993 |
|
|
2022
Q3 | $162M | Sell |
2,384,677
-2,038,867
| -46% | -$112M | 0.01% | 818 |
|
|
2022
Q2 | $141M | Buy |
4,423,544
+967,532
| +28% | +$28.3M | 0.01% | 941 |
|
|
2022
Q1 | $120M | Buy |
3,456,012
+284,877
| +9% | +$8.52M | 0.01% | 1167 |
|
|
2021
Q4 | $92.8M | Buy |
3,171,135
+63,408
| +2% | +$1.96M | ﹤0.01% | 1356 |
|
|
2021
Q3 | $79.2M | Buy |
3,107,727
+806,900
| +35% | +$23.7M | ﹤0.01% | 1454 |
|
|
2021
Q2 | $80.6M | Buy |
2,300,827
+449,419
| +24% | +$17.5M | ﹤0.01% | 1477 |
|
|
2021
Q1 | $75.4M | Sell |
1,851,408
-424,301
| -19% | -$19.5M | ﹤0.01% | 1450 |
|
|
2020
Q4 | $98.6M | Buy |
2,275,709
+635,550
| +39% | +$31.3M | 0.01% | 1157 |
|
|
2020
Q3 | $90.4M | Buy |
1,640,159
+70,954
| +5% | +$4.51M | 0.01% | 1035 |
|
|
2020
Q2 | $99.1M | Sell |
1,569,205
-618,178
| -28% | -$42.4M | 0.01% | 969 |
|
|
2020
Q1 | $112M | Buy |
2,187,383
+29,555
| +1% | +$1.98M | 0.01% | 800 |
|
|
2019
Q4 | $172M | Sell |
2,157,828
-213,639
| -9% | -$12.7M | 0.01% | 755 |
|
|
2019
Q3 | $115M | Buy |
2,371,467
+181,054
| +8% | +$9.44M | 0.01% | 919 |
|
|
2019
Q2 | $115M | Sell |
2,190,413
-207,602
| -9% | -$11.9M | 0.01% | 939 |
|
|
2019
Q1 | $127M | Buy |
2,398,015
+209,919
| +10% | +$10.3M | 0.01% | 874 |
|
|
2018
Q4 | $89.8M | Sell |
2,188,096
-405,068
| -16% | -$15.2M | 0.01% | 963 |
|
|
2018
Q3 | $98.5M | Buy |
2,593,164
+173,001
| +7% | +$7.66M | 0.01% | 1087 |
|
|
2018
Q2 | $109M | Buy |
2,420,163
+373,768
| +18% | +$17M | 0.01% | 977 |
|
|
2018
Q1 | $98.8M | Buy |
2,046,395
+224,586
| +12% | +$12.5M | 0.01% | 1014 |
|
|
2017
Q4 | $71.7M | Sell |
1,821,809
-181,611
| -9% | -$6.78M | 0.01% | 1212 |
|
|
2017
Q3 | $62.2M | Sell |
2,003,420
-134,903
| -6% | -$3.79M | 0.01% | 1245 |
|
|
2017
Q2 | $58.5M | Buy |
2,138,323
+1,465,595
| +218% | +$43.6M | 0.01% | 1267 |
|
|
2017
Q1 | $24.8M | Buy |
672,728
+382,744
| +132% | +$9.64M | ﹤0.01% | 1780 |
|
|
2016
Q4 | $4.17M | Buy |
289,984
+4,024
| +1% | +$70.7K | ﹤0.01% | 2783 |
|
|
2016
Q3 | $6.59M | Buy |
285,960
+106,934
| +60% | +$2.04M | ﹤0.01% | 2412 |
|
|
2016
Q2 | $2.97M | Buy |
179,026
+85,154
| +91% | +$1.72M | ﹤0.01% | 2878 |
|
|
2016
Q1 | $1.49M | Buy |
93,872
+5,764
| +7% | +$102K | ﹤0.01% | 3090 |
|
|
2015
Q4 | $2.85M | Buy |
88,108
+12,875
| +17% | +$558K | ﹤0.01% | 2847 |
|
|
2015
Q3 | $3.17M | Buy |
+75,233
| New | +$3.55M | ﹤0.01% | 2771 |
|
Other funds holding GBT
State Street's GBT Position: Q4 2022 in Review
State Street sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 2,384,677 shares — an estimated $162M sold.
State Street first reported a position in GBT in Q3 2015 and held it in 29 quarters. The position peaked at $172M in Q4 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- State Street reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- State Street sold 2,384,677 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $162M.
- State Street first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 29 quarters.
- State Street's Global Blood Therapeutics, Inc. position peaked at $172M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on State Street's 13F filing for Q4 2022, filed 14 Feb 2023.